Evidence map›Paper›PMID 25998490›Full record

ArticleStem cell research & therapy2015

Osteopontin mediates survival, proliferation and migration of neural stem cells through the chemokine receptor CXCR4.

Monika Rabenstein, Joerg Hucklenbroich, Antje Willuweit, Anne Ladwig, Gereon Rudolf Fink, Michael Schroeter, Karl-Josef Langen, Maria Adele Rueger

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Non-invasive brain stimulation for osteoarthritis.Frontiers in aging neuroscience · 2022
    Review
  13. Article
  14. Immunohistochemical Detection of Neural Stem Cells and Glioblastoma Stem Cells in the Subventricular Zone of Glioblastoma Patients.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021
    Article
  15. Review
  16. Evidence-based complementary and alternative medicine : eCAM · 2021
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Monika RabensteinDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. monika.rabenstein@uk-koeln.de.
Joerg HucklenbroichDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. joerg@germanynet.de.
Antje WilluweitMedical Imaging Physics, Institute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany. a.willuweit@fz-juelich.de.
Anne LadwigDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. anne.ladwig@uk-koeln.de.
Gereon Rudolf FinkDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. G.R.Fink@fz-juelich.de.
Michael SchroeterDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. michael.schroeter@uk-koeln.de.
Karl-Josef LangenMedical Imaging Physics, Institute of Neuroscience and Medicine (INM-4), Research Centre Juelich, Juelich, Germany. k.j.langen@fz-juelich.de.
Maria Adele RuegerDepartment of Neurology, University Hospital of Cologne, Cologne, Germany. adele.rueger@uk-koeln.de.
University Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOsteopontin (OPN) is a phosphoglycoprotein with important roles in tissue homeostasis, wound healing, immune regulation, and stress responses. It is expressed constitutively in the brain and upregulated during neuroinflammatory responses; for example, after focal cerebral ischemia. To date, its effects on neural stem cells (NSC) remain to be elucidated and are, accordingly, the subject of this study.

methodPrimary fetal rat NSC were cultured as homogenous monolayers and treated with different concentrations of OPN. Fundamental properties of NSC were assessed following OPN exposure, including proliferative activity, survival under oxidative stress, migration, and differentiation potential. To elucidate a putative action of OPN via the CXC chemokine receptor type 4 (CXCR4), the latter was blocked with AMD3100. To investigate effects of OPN on endogenous NSC in vivo, recombinant OPN was injected into the brain of healthy adult rats as well as rats subjected to focal cerebral ischemia. Effects of OPN on NSC proliferation and neurogenesis in the subventricular zone were studied immunohistochemically.

resultsOPN dose-dependently increased the number of NSC in vitro. As hypothesized, this effect was mediated through CXCR4. The increase in NSC number was due to both enhanced cell proliferation and increased survival, and was confirmed in vivo. Additionally, OPN dose-dependently stimulated the migration of NSC via CXCR4. Moreover, in the presence of OPN, differentiation of NSC led to a significant increase in neurogenesis both in vitro as well as in vivo after cerebral ischemia.

conclusionData show positive effects of OPN on survival, proliferation, migration, and neuronal differentiation of NSC. At least in part these effects were mediated via CXCR4. Results suggest that OPN is a promising substance for the targeted activation of NSC in future experimental therapies for neurological disorders such as stroke.

Indexed as

AnimalsCell MovementCell ProliferationCells, CulturedCell SurvivalFetusImmunohistochemistryNeural Stem CellsNeurogenesisOsteopontinRatsReceptors, CXCR4Signal TransductionOsteopontinReceptors, CXCR4

Identifiers

PMID25998490
PMCPMC4464234
OpenAlexW1550368491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.